HomeCompareRTGOF vs JNJ

RTGOF vs JNJ: Dividend Comparison 2026

RTGOF yields 5128.21% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RTGOF wins by $79569732907105.77M in total portfolio value
10 years
RTGOF
RTGOF
● Live price
5128.21%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79569732907105.80M
Annual income
$76,630,238,974,256,940,000.00
Full RTGOF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RTGOF vs JNJ

📍 RTGOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRTGOFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RTGOF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RTGOF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RTGOF
Annual income on $10K today (after 15% tax)
$435,897.44/yr
After 10yr DRIP, annual income (after tax)
$65,135,703,128,118,395,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, RTGOF beats the other by $65,135,703,128,118,395,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RTGOF + JNJ for your $10,000?

RTGOF: 50%JNJ: 50%
100% JNJ50/50100% RTGOF
Portfolio after 10yr
$39784866453552.91M
Annual income
$38,315,119,487,128,470,000.00/yr
Blended yield
96.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RTGOF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RTGOF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRTGOFJNJ
Forward yield5128.21%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$79569732907105.80M$30.3K
Annual income after 10y$76,630,238,974,256,940,000.00$4,689.40
Total dividends collected$79371015555921.34M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RTGOF vs JNJ ($10,000, DRIP)

YearRTGOF PortfolioRTGOF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$523,521$512,820.51$10,592$272.30+$512.9KRTGOF
2$25,651,013$25,090,846.53$11,289$357.73+$25.64MRTGOF
3$1,176,399,845$1,148,953,261.06$12,123$472.89+$1176.39MRTGOF
4$50,504,527,129$49,245,779,294.25$13,141$629.86+$50504.51MRTGOF
5$2,029,919,943,175$1,975,880,099,147.06$14,408$846.81+$2029919.93MRTGOF
6$76,392,776,643,917$74,220,762,304,720.03$16,021$1,151.60+$76392776.63MRTGOF
7$2,692,188,100,364,169$2,610,447,829,355,177.00$18,122$1,588.22+$2692188100.35MRTGOF
8$88,858,048,683,110,320$85,977,407,415,720,670.00$20,930$2,228.20+$88858048683.09MRTGOF
9$2,747,190,591,447,524,000$2,652,112,479,356,595,700.00$24,792$3,191.91+$2747190591447.50MRTGOF
10$79,569,732,907,105,800,000$76,630,238,974,256,940,000.00$30,274$4,689.40+$79569732907105.77MRTGOF

RTGOF vs JNJ: Complete Analysis 2026

RTGOFStock

ArtGo Holdings Limited, an investment holding company, primarily engages in the mining, processing, trading, and sale of marble stones and commodity trading businesses in the People's Republic of China. It operates in two segments, Marble Products and Others. The company offers marble slabs, standard cut to size marble, antique series, water jet, border series, and marble-related crafts for bathroom and tailor-made household products; and calcium carbonate products. It also provides cargo handling services; and wholesales and retails decorating materials and chemical products. In addition, the company is involved in the provision of technical services for stone processing; warehousing, logistics, and sale of mineral products; and mining investment and mining planting projects. The company was formerly known as ArtGo Mining Holdings Limited and changed its name to ArtGo Holdings Limited in March 2015. ArtGo Holdings Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

Full RTGOF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RTGOF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RTGOF vs SCHDRTGOF vs JEPIRTGOF vs ORTGOF vs KORTGOF vs MAINRTGOF vs ABBVRTGOF vs MRKRTGOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.